Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived A | Diskussion im Forum

[equityowner]

Back office.......

auch ich war überrascht. Musste für mehrere Jahre nachzahlen und bedauerlich ist die Tatschae, dass die Gebühren nicht steuerlich anerkannt werden.

[SharonM]

Externe Back Office Gebühren Adaptimmune

Inzwischen ist ja einiges passiert, Merger mit TCR2 und steiler Weg nach unten.
Jetzt zum Thema Back Office Gebühren. Ich bin schon sehr lange in Adapt investiert - Adaptimmune ist ja eine ADR - im März 2023 und im Juni 2023 werden mir plötzlich Back Office Gebühren (rückwirkend für 2021 im März und für 2022 im Juni 2023) vom Broker einbehalten. Höhe der Gebühren mit 0,02 $ pro Aktie ist okay, nur das rückwirkend stört mich. Wären die Back Office Gebühren zeitnah berechnet worden, hätte ich in 2021,2022 und 2023 nicht mehr nachgekauft.
Was habt Ihr für Erfahrungen bezüglich der Back office Gebühren mit Adapt gemacht ?

[Irishnelly85]

Antwort auf Beitrag Nr.: 71.129.826 von LukaDoncic am 17.03.22 13:53:36

Wenn so ein grosser Konzern Gen/Roche mit so einem Partner arbeitet denke ich ist was dran. Ich überlege mir einzusteigen, Cell and Gen ist sehr ein interessanter Markt

[LukaDoncic]

warum hat sich dann genentech adap für ihre allogenen pläne als partner ausgesucht? wer ist denn adap voraus?

[bcgk]

Antwort auf Beitrag Nr.: 69.603.840 von Sven_Bonn am 15.10.21 08:52:01

Allogeneic ist megainteressant, aber da sind andere Unternehmen Jahre voraus. Die autologen Behandlungsversuche halte ich für wenig erfolgsversprechend, weil viel zu teuer in der praktischen Umsetzung.

[Sven_Bonn]

Patentnews

US GSK/ Adaptimmune patent published for the second generation NY-ESO CD8 construct.
"observed that CD4+CD8α NY-ESO-1 c259 T cells secrete many chemokines and cytokines that mediate effector T cell recruitment, with a trend for elevated levels in comparison with CD4+NY-ESO-1 c259 T cells. These include IFNα, shown to upregulate HLA class 1 in cancer; the chemokine IP-10, thought to play an important role in recruiting activated T cells and a is a potent inhibitor of angiogenesis in mice; and RANTES, a potent chemoattractant for many cell types including NK cells and memory T cells. These results could indicate that co-expression of CD8α may result in increased trafficking of T cells and additional anti-tumor effects"

Quelle: https://patentscope.wipo.int/search/en/detail.jsf?docId=US33…

[Sven_Bonn]

Roche bets big on off-the-shelf cancer cell therapy with Adaptimmune deal

Sehr interessanter Artikel.. (ist aber schon vom 7.9.21)

Dive Brief:

Roche has acquired rights to a group of off-the-shelf cancer cell therapy programs from Adaptimmune, agreeing to work with the biotech on five "shared cancer targets" and some additional personalized T cell therapies as well, the companies announced Tuesday.
The Swiss drugmaker will pay Adaptimmune $150 million now and could add another $150 million over five years if the deal remains active that long. The deal could be worth more than $3 billion if various milestones are met, though that money isn't guaranteed. Adaptimmune can also opt for royalties on sales or to split costs and profits for each project, according to the deal's terms.
The alliance marks the most significant investment for Roche in cell therapy, a field of research the drugmaker has been slower to embrace than firms like Novartis, Gilead and Bristol Myers Squibb. Prior to Tuesday's announcement, the firm had indicated interest through smaller deals with Tusk Therapeutics and SQZ Biotechnologies.

Quelle:
https://www.biopharmadive.com/news/roche-adaptimmune-cell-th…

[Sven_Bonn]

Adaptimmune Therapeutics: Adaptimmune Announces Clinical Responses Across Five Solid Tumor Indications With An Overall Response Rate Of 36% And Promising Early Durability From Its Next-Generation Surp

he following excerpt is from the company's SEC filing.
- Confirmed complete response in ovarian cancer, and confirmed partial responses in ovarian, head and neck, esophagogastric junction, bladder, and synovial sarcoma cancers -
- Majority of patients experienced antitumor activity with a disease control rate of 86% -
- ADP-A2M4CD8 cell therapy shows improved tumor cell killing and engagement of the broader immune system to fight cancer -
PHILADELPHIA, PA. and OXFORD, UK, September 13, 2021 –
Adaptimmune Therapeutics plc
(Nasdaq: ADAP), a leader in cell therapy to treat cancer, announced updated data from its Phase 1 SURPASS trial in multiple solid tumors
to be presented in a digital poster at the upcoming European Society for Medical Oncology (ESMO) annual meeting
. The poster will be displayed on the ESMO congress web site on Thursday, September 16
. The Company has also released a video of Adrian Rawcliffe, Adaptimmune’s Chief Executive Officer (CEO), and Elliot Norry, Adaptimmune’s Chief Medical Officer, describing these data in more detail that can be accessed here:
https://bit.ly/38ZQCGt
“It is no longer a question of whether our SPEAR T-cells are effective against a range of MAGE-A4 expressing tumors — they undoubtedly are. Now, our focus is on turning them into approved therapies. This begins with ongoing recruitment in this SURPASS trial for people with lung, bladder, gastroesophageal, head and neck, and now ovarian cancer, and continues with the recently initiated SURPASS 2 trial in esophageal and EGJ cancers,” said Adrian Rawcliffe, Adaptimmune’s CEO. “These data bring us closer to identifying further indications to take into late-stage development and confirm our expertise in developing and enhancing cell therapies. ADP-A2M4CD8 does exactly what we designed it to do — kill cancer cells and more effectively engage the broader immune system to deliver improved potency and clinical benefit.”
Dr. David Hong, Professor, Deputy Chairman in the Department of Investigational Cancer Therapeutics (Phase I Program) at The University of Texas MD Anderson Cancer Center said, “We are encouraged by these promising early data from the SURPASS trial. Having previously seen strong responses with afami-cel, this next-generation cell therapy appears safe and demonstrated antitumor activity for a majority of patients across many cancer indications.”
Topline results from the Phase 1 SURPASS trial (data cut-off August 2, 2021)
Emerging efficacy and durability data are promising with responses in five solid tumor indications
As of the data cut-off date, 25 patients had received the next-generation cell therapy, ADP-A2M4CD8, in the Phase 1 SURPASS trial, 22 patients were evaluable for efficacy with at least one post-baseline scan meeting the ≥4-week duration for evaluation of stable disease
All patients had advanced metastatic disease and had received multiple prior regimens of systemic therapy (median: 3; range 1-6)
The overall response rate was 36% and the disease control rate was 86%
There was a complete response reported in a patient with ovarian cancer, which remains ongoing at 6 months post-infusion (data on file at Adaptimmune)
Initial durability is encouraging. As of the data cut-off, 11 patients remain on study. Of the 8 responders, 5 remain in response with some remaining progression free >24 weeks
Best Overall Response (n=22)*
Overall, n (%)
Cancer Indication
(n=1 unless otherwise noted)
Complete response (CR)
1 (4.5)
Ovarian
Partial response (PR)
7 (31.8)
Ovarian (2); head and neck (2)**; esophagogastric junction (EGJ)**; bladder; synovial sarcoma
Stable disease (SD)
11 (50.0)
Ovarian cancer (3); EGJ (2); esophageal (2); lung cancer, MRCLS, melanoma,
Progressive disease (PD)
3 (13.6)
EGJ, lung, ovarian
Overall response rate (CR, PR)
8 (36.4)
Disease control rate (CR, PR, SD)
19 (86.4)
Of 25 patients who received ADP-A2M4CD8, 3 were not evaluable at the time of data cut-off: 2 patients (ovarian or esophageal cancers) did not have post-baseline scans; 1 patient (EGJ) had a post-baseline scan that did not meet the ≥4-week duration for evaluation of stable disease
** One PR in head and neck cancer and one PR in EGJ cancer were reported previously at SITC 2020
ADP-A2M4CD8 demonstrated an acceptable safety profile
Eighteen (72%) patients experienced cytokine release syndrome (CRS) related to T-cell infusion, most of which were lower grade: Grade 1 or 2 (n=14); Grade 3 (n=4)
The most common serious adverse event (SAE) of any grade (> 30% of patients) was CRS
Four (16%) patients experienced immune effector cell-associated neurotoxicity syndrome (ICANS) related to T-cell infusion: Grade 1 (n=1); Grade 2 (n=1); Grade 3 (n=2)
Five (20%) patients experienced prolonged cytopenia at Week 4
One patient experienced a fatal (Grade 5) SAE of pancytopenia (previously reported in the Company’s 10K Report filed with the Securities and Exchange Commission on February 25, 2021)
ADP-A2M4CD8 was designed to be more potent than the first-generation product
Adaptimmune’s Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell therapies are a mix of CD8+ (“killer”) and CD4+ (“helper”) T-cells engineered with a T-cell receptor (TCR) designed with Adaptimmune’s proprietary affinity enhancement technology to recognize a cancer target
ADP-A2M4CD8 is a next-generation T-cell therapy engineered to target MAGE-A4 positive tumors, and to express a CD8α co-receptor
ADP-A2M4CD8 uses the same engineered T-cell receptor that recognizes MAGE-A4 as Adaptimmune’s first-generation T-cell therapy, afami-cel, which has shown compelling results in synovial sarcoma and myxoid/round cell liposarcoma (presented at ASCO 2021)
Co-expression of CD8α adds CD8+ killer cell capability to CD4+ helper T-cells, while maintaining or enhancing the CD4+ helper function (i.e., producing the inflammatory cytokines IFN-γ and IL-2)
Initial translational data confirm that ADP-A2M4D8 is more potent and better engages the immune system, compared to the first-generation product
Patient manufactured product and serum samples from the first-generation Phase 1 afami-cel trial and the next-generation SURPASS trial were compared
In vitro
tumor cell killing assays confirm that the next-generation product results in greater tumor cell killing by CD4+ SPEAR T-cells
Analyses of patient serum samples demonstrate increases in a subset of 22 measured serum cytokines confirming increased helper function of the next-generation CD4+ T-cells and engagement of the broader immune system
Additional serum analyses showed increased serum IL-12 in the SURPASS trial versus the first-generation Phase 1 trial, which is also consistent with engagement of the broader immune system, including dendritic cells, as IL-12 is not known to be produced by T-cells
Conclusions from the Phase 1 SURPASS Trial Data at ESMO
Initial efficacy and durability data are encouraging with responses across five different solid tumors including a complete response in a patient with ovarian cancer ongoing at 6 months
The safety profile of the next-generation ADP-A2M4CD8 cell therapy was acceptable
Data confirm preclinical observations that the enhanced TCR interaction in ADP-A2M4CD8 results in a more potent product
Safety and efficacy, including duration of response, will continue to be evaluated in the ongoing SURPASS trial, which is enrolling eligible patients with gastroesophageal, head and neck, lung, bladder, and ovarian cancers
A Phase 2 trial, SURPASS-2, has initiated for patients with esophageal and EGJ cancers
Overview of Phase 1 SURPASS trial design
This is a Phase 1, open-label, dose escalation clinical trial designed to evaluate the safety and antitumor activity of ADP-A2M4CD8 in patients
with MAGE-A4+ tumors in the context of HLA-A*02
This is a first-in-human dose-escalation trial using a modified 3+3 design, with 2 dose cohorts plus an expansion cohort
The number of transduced cells ranged from 0.8x10
to 1.2x10
(Cohort 1 complete), 1.2x10
to 6.0x10
(Cohort 2 complete), and 1.2x10
to 10.0x10
(Expansion)
Dose-limiting toxicities are adjudicated by a Safety Review Committee, regardless of the investigator’s attribution
Responses are assessed per RECIST v1.1
About Adaptimmune
Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors.
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 9, 2021 and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.
Adaptimmune Contacts:
Media Relations:
Sébastien Desprez — VP, Corporate Affairs and Communications
T: [phone]
M: [phone]
[e-mail]
Investor Relations:
Juli P. Miller, Ph.D. — VP, Investor Relations
T: [phone]
M: [phone]
[e-mail]

[Sven_Bonn]

Guten Morgen,

noch einmal eine schöne Zusammenfassung des gestrigen Deals:


Dive Brief:

Roche has acquired rights to a group of off-the-shelf cancer cell therapy programs from Adaptimmune, agreeing to work with the biotech on five "shared cancer targets" and some additional personalized T cell therapies as well, the companies announced Tuesday.
The Swiss drugmaker will pay Adaptimmune $150 million now and could add another $150 million over five years if the deal remains active that long. The deal could be worth more than $3 billion if various milestones are met, though that money isn't guaranteed. Adaptimmune can also opt for royalties on sales or to split costs and profits for each project, according to the deal's terms.
The alliance marks the most significant investment for Roche in cell therapy, a field of research the drugmaker has been slower to embrace than firms like Novartis, Gilead and Bristol Myers Squibb. Prior to Tuesday's announcement, the firm had indicated interest through smaller deals with Tusk Therapeutics and SQZ Biotechnologies.

Dive Insight:

Adaptimmune, like companies such as Bluebird Bio and Cellectis, remains one of the more prominent independent developers of cancer cell therapies. Early pioneers Kite Therapeutics and Juno Therapeutics were snapped up by Gilead and Celgene, respectively, with the Juno portfolio now in the hands of Bristol Myers Squibb.

The treatments Kite and Juno developed and their acquirers now sell, however, are logistically complex. They, as well as another drug from Novartis, require a laborious multi-week production process. Side effects can also be severe, meaning patients have to stay in or near a specialized hospital after the engineered cells are reinfused back into the body.

Adaptimmune has been developing such "autologous" treatments, too. But unlike many of its peers, the biotech has focused on solid tumors, a tougher cell therapy target. Alongside that effort has been an emerging plan to develop off-the-shelf, or "allogeneic" therapies, that could bypass many of the problems autologous treatments face if they prove safe and effective in clinical testing.

Adaptimmune already has a long-running partnership in place with GlaxoSmithKline for its autologous work. But Roche has taken a significant interest in its off-the-shelf research, a notable investment from a company that, while known for its cancer business, had yet to make a large bet on cell therapy.

The deal calls for Adaptimmune to develop T cell-based treatments using its in-house technology, which reprograms donor stem cells that can mature into other types of cells. Roche will be responsible for engineering the receptors on those cells that can latch onto tumors, as well as helping out with development and commercialization.

The additional revenue will help Adaptimmune sustain operations through early 2024 as it attempts to push forward seven clinical programs. The company had $285 million in cash and securities as of June 30, a sum that had declined by $83 million through the first six months of 2021.


Quelle:
https://www.biopharmadive.com/news/roche-adaptimmune-cell-th…

[Sven_Bonn]

Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies

Adaptimmune Therapeutics plc
Tue, September 7, 2021, 1:00 PM·5 min read
In this article:

- Combining both companies’ cell therapy leadership and expertise, the collaboration covers the research and development of “off-the-shelf” cell therapies for up to five shared cancer targets and the development of a novel allogeneic personalized cell therapy platform -

- Adaptimmune will receive $150 million upfront, $150 million over the next five years in additional payments, and development, regulatory and commercial milestones payments potentially exceeding $3 billion in aggregate value, as well as royalties, across multiple programs -

- The Company will host a virtual update about its allogeneic platform on Thursday, September 9 at 08:00 a.m. EDT (01:00 p.m. BST) -

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, announced today that it has entered into a strategic collaboration and license agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) to develop and commercialize allogeneic cell therapies to treat multiple oncology indications.

“We are proud to partner with Genentech, given their commitment to patients and science in the cancer immunology field. This collaboration broadens Adaptimmune’s leadership position in developing allogeneic cell therapies building on our in-depth knowledge gained from our autologous clinical programs,” said Adrian Rawcliffe, Adaptimmune’s Chief Executive Officer. “Through this collaboration, our platform will form the basis of a personalized allogeneic cell therapy vision, where any patient can receive a T-cell product for their cancer; a significant step towards our goal of making cell therapies both curative and mainstream.”

“We believe allogeneic cell therapies could be a game-changing approach for developing personalized therapy platforms based on individual cancer patients’ unique needs,” said James Sabry, M.D., Ph.D., global head of Pharma Partnering, Roche. “This partnership, which combines Adaptimmune’s allogeneic platform with Genentech’s expertise in developing personalized therapies, complements our other efforts to discover and develop personalized cell therapies. It holds the promise to change how we treat cancer and brings us another step closer to making personalized healthcare a reality.”

QUELLE:
https://finance.yahoo.com/news/adaptimmune-enters-strategic-…